Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05317026

Increased Early Pain Relief by Adding Vertebroplasty to SBRT

Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2024-08-07

50

Participants Needed

2

Research Sites

214 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of treating metastases is to preserve stability and neurological function while reducing pain. The actual standard of care is stereotaxic body radiation therapy (SBRT) alone in non-surgical patients. The added value of vertebroplasty to SBRT is not well documented in the literature, nor whether performing vertebroplasty before radiotherapy treatment leads to a reduction in the rate of fractures and post-SBRT pain.

CONDITIONS

Official Title

Increased Early Pain Relief by Adding Vertebroplasty to SBRT

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histological evidence of cancer
  • Spinal and vertebral bone metastases from T5 to L5 documented by imaging
  • Pain related to metastases of 4 or higher on a 0-10 scale
  • Karnofsky performance index greater than 60 (ECOG 0-2)
  • Candidate for stereotactic body radiation therapy (SBRT)
  • Less than 3 consecutive vertebral levels affected
  • Ability to complete follow-up questionnaires on pain, medication, and quality of life
  • Potentially unstable lesions with spinal instability neoplastic score (SINS) of 7 or higher
Not Eligible

You will not qualify if you...

  • Pregnancy or breastfeeding
  • Contraindications to MRI
  • Diagnosis of myeloma, lymphoma, or plasmacytoma
  • Previous radiotherapy at the treatment site
  • Previous surgery at the treatment site
  • Surgical indication with SINS score above 13 or tumor board consensus
  • Bilsky score 2 or higher, or severe/progressive neurological symptoms
  • Lesion too large for safe vertebroplasty
  • Lesion located above T4, preventing safe fluoroscopic visibility
  • Non-reversible blood clotting disorders
  • Uncontrolled local or systemic infection
  • Expected survival less than 6 months
  • Inability or refusal to undergo SBRT or vertebroplasty treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

CHUM

Montreal, Quebec, Canada, H2X0C1

Actively Recruiting

2

Véronique Freire

Montreal, Quebec, Canada

Actively Recruiting

Loading map...

Research Team

V

Véronique Freire, MD

CONTACT

F

Fidaa Al-Shakfa, M.sc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here